登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《MedRxiv，3月6日，Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-07

  • Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients

    Xiaoping Chen, Jiaxin Ling, Pingzheng Mo, Yongxi Zhang, Qunqun Jiang, Zhiyong Ma, Qian Cao, Wenjia Hu, Shi Zou, Liangjun Chen, Lei Yao, Mingqi Luo, Tielong Chen, Liping Deng, Ke Liang, Shihui Song, Rongrong Yang, Ruiying Zheng, Shicheng Gao, Xien Gui, Hengning Ke, Wei Hou, Åke Lundkvist, Yong Xiong

    doi: https://doi.org/10.1101/2020.03.03.20030437

    Abstract

    Background: Viral clearance is one important indicator for the recovery of SARS-CoV-2 infected patients. Suboptimal T and B cell responses can delay viral clearance in MERS and SARS patients. The role of leukomonocytes in viral clearance of COVID-19 patients is not yet well defined.Methods: From January 26 to February 28, 2020, an observational study was launched at Zhongnan Hospital of Wuhan University, Wuhan, China. We enrolled 25 laboratory-confirmed COVID-19 patients, whose throat-swab specimens were tested positive for SARS-CoV-2 infection by qRT-PCR.

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.medrxiv.org/content/10.1101/2020.03.03.20030437v1
68浏览量
原文链接
相关报告

  • 《MedRxiv，3月24日，Hypertension and Diabetes Delay the Viral Clearance in COVID-19 Patients》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-25
    • Hypertension and Diabetes Delay the Viral Clearance in COVID-19 Patients Xiaoping Chen, Wenjia Hu, Jiaxin Ling, Pingzheng Mo, Yongxi Zhang, Qunqun Jiang, Zhiyong Ma, Qian Cao, Liping Deng, Shihui Song, Ruiying Zheng, Shicheng Gao, Hengning Ke, Xien Gui, Åke Lundkvist, Jinlin Li, Johanna F Lindahl, Yong Xiong doi: https://doi.org/10.1101/2020.03.22.20040774 Abstract Objectives: Comorbidities have significant indications for the disease outcome of COVID-19, however which underlying diseases that contribute the most to aggravate the conditions of COVID-19 patients is still largely unknown. SARS-CoV-2 viral clearance is a golden standard for defining the recovery of COVID-19 infections. To dissect the underlying diseases that could impact on viral clearance, we enrolled 106 COVID-19 patients who were hospitalized in the Zhongnan Hospital of Wuhan University, Wuhan, China between Jan 5 and Feb 25, 2020. Methodology: We comprehensively analyzed demographic, clinical and laboratory data, as well as patient treatment records. Survival analyses with Kaplan-Meier and Cox regression modelling were employed to identify factors influencing the viral clearance negatively. Results: We found that increasing age, male gender, and angiotensin-converting enzyme 2 (ACE2) associated factors (including hypertension, diabetes, and cardiovascular diseases) adversely affected the viral clearance. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    26浏览量
    原文链接

  • 《Nature，12月24日，Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2021-02-01
    • Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19 Saskia Trump, Soeren Lukassen, […]Irina Lehmann Nature Biotechnology (2020) Abstract In coronavirus disease 2019 (COVID-19), hypertension and cardiovascular diseases are major risk factors for critical disease progression. However, the underlying causes and the effects of the main anti-hypertensive therapies—angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)—remain unclear. Combining clinical data (n = 144) and single-cell sequencing data of airway samples (n = 48) with in vitro experiments, we observed a distinct inflammatory predisposition of immune cells in patients with hypertension that correlated with critical COVID-19 progression. ACEI treatment was associated with dampened COVID-19-related hyperinflammation and with increased cell intrinsic antiviral responses, whereas ARB treatment related to enhanced epithelial–immune cell interactions. Macrophages and neutrophils of patients with hypertension, in particular under ARB treatment, exhibited higher expression of the pro-inflammatory cytokines CCL3 and CCL4 and the chemokine receptor CCR1. Although the limited size of our cohort does not allow us to establish clinical efficacy, our data suggest that the clinical benefits of ACEI treatment in patients with COVID-19 who have hypertension warrant further investigation.
    53浏览量
    原文链接